“Nobiletin acts as a potential anticancer agent against osteosarcoma by regulating ERK and AKT signaling pathways”, Bangladesh J Pharmacol, vol. 9, no. 3, pp. 406–412, Sep. 2014, doi: 10.3329/bjp.v9i3.19567.